Trial
NCT01157949
A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)
Phase IIIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Cedars-Sinai Medical Center
Collaborators
Genzyme, a Sanofi Company
Condition
Cardiac Allograft Vasculopathy
Intervention
Thymoglobulin
Why stopped
PI not planning to pursue this study and it was never IRB approved.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-03-14